CCO Oncology Podcast

Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

Episode Summary

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses using targeted therapies in patients with <i>FLT3</i>- or <i>IDH1/2</i>-mutated AML.

Episode Notes

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:

• Approved and emerging treatment options for FLT3-mutated AML
• Management of adverse events associated with FLT3 inhibitors
• Therapies for IDH1- and IDH2-mutated AML
• Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors

Presenters:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida